| Outcome Measures: |
Primary: Maximum postprandial (breakfast, lunch, dinner) blood glucose added value., Compared with placebo, the maximum change in glucose from baseline at D7., 7 days|Blood glucose AUC (AUC 0-4,AUC 4-10, AUC 10-14, AUC 0-24) in different periods., Compared with placebo, the mean change in glucose AUC from baseline at D7., 7 days|The Safety and tolerance of SY-009，Collecting Number of subjects with adverse events as assessed by CTCAE V5.0., Number of subjects with adverse events, major adverse events, serious adverse events, abnormal Laboratory Values, abnormal vital signs, Abnormal physical examination, Abnormal ECG data，Gastrointestinal adverse reactions (diarrhea, etc.) and hypoglycemia events., 7 days|C-peptide concentration changes before and after meal., Compared with placebo, the mean change from baseline at D7., 7 days|The changes of insulin concentration before and after meal., Compared with placebo, the mean change from baseline at D7., 7 days|GLP-1 concentration changes before and after meal., Compared with placebo, the mean change from baseline at D7., 7 days|GIP concentration changes before and after meal., Compared with placebo, the mean change from baseline at D7., 7 days | Secondary: Peak concentration (Cmax), after the first dose, 1 day|Peak time (Tmax), after the first dose, 1 day|Terminal elimination rate constant (λ z), after the first dose, 1 day|Terminal elimination half-life (T1 / 2), after the first dose, 1 day|Area under the drug time curve from 0 to the last detectable time (auc0-t), after the first dose, 1 day|Area under the drug time curve (auc0 - ∞) from 0 to infinite time, after the first dose, 1 day|Auc0 - ∞ extrapolation percentage (% aucex), after the first dose, 1 day|Apparent clearance (CL / F), after the first dose, 1 day|Apparent distribution volume (VZ / F)., after the first dose, 1 day|Steady state peak concentration (Cmax, SS)., After reaching steady state, 7 days|Steady state peak time (Tmax, SS)., After reaching steady state, 7 days|Steady state terminal elimination half-life (T1 / 2, SS)., After reaching steady state, 7 days|Area under drug time curve (auc0-t, SS) from steady state 0 to last detectable time., After reaching steady state, 7 days|The area under the drug time curve (auc0 - ∞, SS) of steady state from 0 to infinite time., After reaching steady state, 7 days|Auc0 - ∞ extrapolation percentage (% aucex), After reaching steady state, 7 days|Accumulation ratio (rauc, rcmax), After reaching steady state, 7 days|Stable Valley concentration (ctrough, SS)., After reaching steady state, 7 days
|
